1月13日，长春高新盘中上涨2.01%，截至10:13，报105.65元/股，成交7.11亿元，换手率1.72%，总市值 430.99亿元。 截至9月30日，长春高新股东户数10.41万，较上期减少4.63%；人均流通股3840股，较上期增加4.85%。 2025年1月-9月，长春高新实现营业收入98.07亿元，同比减少5.60%；归母净利润11.65亿元，同比减少 58.23%。 分红方面，长春高新A股上市后累计派现47.91亿元。近三年，累计派现32.59亿元。 机构持仓方面，截止2025年9月30日，长春高新十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股974.51万股，相比上期增加130.70万股。华泰柏瑞沪深300ETF（510300）位居第五大流通 股东，持股551.83万股，相比上期减少24.38万股。招商国证生物医药指数A（161726）位居第六大流通 股东，持股430.37万股，相比上期减少73.67万股。兴全合润混合A（163406）位居第七大流通股东，持 股412.79万股，相比上期减少2.63万股。易方达沪深300医药ETF（512010）位居第八大流通股东，持股 40 ...

证券之星消息，1月12日生物制品板块较上一交易日下跌0.06%，三生国健领跌。当日上证指数报收于 4165.29，上涨1.09%。深证成指报收于14366.91，上涨1.75%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300239 | 东宝生物 | 6.60 | 10.92% | 57.51万 | 3.66亿 | | 000661 | 长春高新 | 103.57 | 5.79% | 16.94万 | 17.25亿 | | 002581 | ST未名 | 7.83 | 4.96% | 7.15万 | 5430.49万 | | 920575 | 康乐卫士 | 9.23 | 3.82% | 7.18万 | 6494.41万 | | 301047 | 义翘神州 | 73.86 | 2.46% | 1.67万 | 1.23亿 | | 000534 | 万泽股份 | 23.21 | 2.38% | 30.77万 | 7.04亿 | | 688670 | 金貞克 | 21 ...

1月12日，长春高新涨5.09%，截至发稿，报102.88元/股，成交8.22亿元，换手率2.07%，总市值419.69 亿元。 截至发稿，刘润哲累计任职时间3年88天，现任基金资产总规模16.77亿元，任职期间最佳基金回报 20.1%， 任职期间最差基金回报1.92%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，创金合信基金旗下1只基金重仓长春高新。创金合信鑫祥混合A（010605）三季度持有股数 7.69万股，占基金净值比例为0.7%，位居第三大重仓股。根据测算，今日浮盈赚取约38.3万元。 创金合信鑫祥混合A（010605）成立日期2021年2月4日，最新规模2.18亿。今年以来收益0.88%，同类 排名7492/9012；近一年收益8.33%，同类排名6699/8157；成立以来收益28.33%。 创金合信鑫祥混合A（010605）基金经理为刘润哲。 资料显示，长春高新技术产业(集团)股份有限公司位于吉林省长春市高新海容广场B座 ...

Core Viewpoint - Changchun High-tech has over 40 candidate drugs in clinical stages or submitted for IND applications, with significant advancements in its pipeline expected by late 2025 [2] Group 1 - As of the last feasible date of the company's prospectus (late September 2025), it has more than 40 candidate drugs in clinical stages or submitted for IND applications [2] - Among these, there are 14 candidates in Phase III clinical trials or new drug application (NDA) stages, and 15 first-class innovative drugs [2] - The company advises stakeholders to refer to its subsequent annual reports for accurate disclosures by the end of 2025 and to check previous announcements for recent clinical progress of key innovative products [2]

Group 1 - The company, Changchun High-tech (000661), responded to investor inquiries on January 9, indicating that different companies have varying research and development (R&D) paths, deployment rhythms, and investment timelines [1] - The company emphasized that the value of technical barriers in specific fields should not be simply measured by quantity [1]

Group 1 - The company was asked by investors if its medical-grade PEG can be applied in brain-machine engineering [2] - The company responded that the PEG-related materials produced by its subsidiary are currently mainly used in its long-acting growth hormone products [2]

每经AI快讯，有投资者在投资者互动平台提问：公司在金派格官网介绍是国内少数具有大规模医用药 用高纯度聚乙二醇原料的生产企业，产品种类齐全，能根据客户的需求，研发并组织生产。请问公司的 peg是否可以应用在脑机工程上或者说有达到脑机工程上的纯度peg产品？ （文章来源：每日经济新闻） 长春高新（000661.SZ）1月9日在投资者互动平台表示，公司下属公司所生产的PEG相关原料目前主要 应用于公司长效生长激素产品中， ...

Group 1 - Jinli Permanent Magnet expects a net profit of 660 million to 760 million yuan for 2025, representing a year-on-year growth of 127% to 161% [1] - Wens Foodstuffs anticipates a net profit of 5 billion to 5.5 billion yuan for 2025, a decrease of 40.73% to 46.12% compared to the previous year [2] - New Open Source plans to repurchase shares worth 40 million to 50 million yuan, with a maximum repurchase price of 25.77 yuan per share [3] Group 2 - Fosun Pharma's subsidiary has had a drug registration application accepted for a new drug targeting ALK-positive non-small cell lung cancer [4] - Leike Film reported a net profit of -86 million yuan for the first three quarters of 2025, indicating a potential annual loss [5] - Crown Stone Technology's application for a specific issuance of A-shares has been accepted by the Shanghai Stock Exchange [6] Group 3 - Dongxin Technology has completed the business registration change for its subsidiary, Lishuan Technology, and has invested 211 million yuan in it [7] - Tianci Materials has increased its commodity futures hedging business limit from 150 million to 300 million yuan [8] - Gaode Infrared's actual controller has reduced his shareholding by 0.54%, bringing his stake down to 62.95% [9] Group 4 - Tianyong Intelligent expects a net profit of 10 million to 15 million yuan for 2025, marking a turnaround from losses [10][11] - China Merchants Energy anticipates a net profit of 6 billion to 6.6 billion yuan for 2025, an increase of 17% to 29% year-on-year [18] - Guangdong Electric Power A's Huizhou Power Plant's Unit 5 has been put into commercial operation, with an investment of 8.05 billion yuan [19] Group 5 - Jianghuai Automobile reported a 42.24% year-on-year increase in sales volume for December 2025 [25] - China Pharmaceutical's subsidiary has received a drug registration certificate for a new medication [26] - TianNeng Co. plans to use up to 12 billion yuan of its own funds for entrusted wealth management [27] Group 6 - Luoyang Huizhong reported a 10.55% month-on-month decrease in sales revenue from live pigs for December 2025 [28] - Baolidi expects a net profit of 145 million to 152 million yuan for 2025, a year-on-year increase of 27.17% to 33.30% [30] - Changchun High-tech's subsidiary has had a melatonin granule registration application accepted [31] Group 7 - Zhongmin Energy reported a 4.46% year-on-year decrease in cumulative on-grid electricity for 2025 [32] - Huaxin Electronics reported a 7.79% year-on-year decrease in consolidated operating revenue for December 2025 [35] - Xiamen Airport reported a 2.79% year-on-year increase in passenger throughput for December 2025 [36] Group 8 - Baiyun Airport reported a 12.27% year-on-year increase in passenger throughput for December 2025 [37] - Pulaike has received a new veterinary drug registration certificate for a chewable tablet [38] - Yunnan Energy Holdings' subsidiary has reduced its stake to 84% after a capital increase [39] Group 9 - Gansu Energy Chemical's new thermal power project has successfully completed trial operation [41] - Zhenghong Technology reported a significant decrease in sales revenue from live pigs for December 2025 [42] - Huasheng Lithium Battery is planning to issue H-shares for listing on the Hong Kong Stock Exchange [43] Group 10 - Jincheng Mining has signed a mining production contract with an estimated total price of approximately 510 million yuan [44] - Microchip Biotech has received approval for clinical trials of a new drug for pancreatic cancer [45] - Yahon Pharmaceutical has completed the first patient enrollment for a Phase I clinical trial of its drug [46]

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received the Acceptance Notice from the National Medical Products Administration for the clinical trial application of its injectable GenSci136, a first-class therapeutic biological product developed in-house, aimed at treating Immunoglobulin A Nephropathy (IgAN) [1] Group 1 - Jinsai Pharmaceutical's injectable GenSci136 is a first-class therapeutic biological product developed for the treatment of IgAN [1] - GenSci136 is a B-cell maturation antigen (BCMA) trimeric fusion protein that can bind to B lymphocyte stimulator (BlyS) and a proliferation-inducing ligand (APRIL) [1] - The drug has the potential to treat various autoimmune diseases characterized by tissue damage caused by pathogenic antibodies, by affecting the survival and differentiation of B lymphocytes and plasma cells [1]

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. ("Jinsai Pharmaceutical"), has received the Acceptance Notice from the National Medical Products Administration for the domestic production drug registration application of melatonin granules, indicating progress in the approval process for this product [1][1]. Group 1 - Jinsai Pharmaceutical's melatonin granules are developed for the pediatric neuropsychiatric field and classified as a Class 4 chemical drug [1]. - The product is designed to activate the MT1 and MT2 receptors in the suprachiasmatic nucleus, which regulates neural activity and demonstrates sleep-inducing effects [1]. - The intended use of the melatonin granules is to improve sleep difficulties associated with neurodevelopmental disorders in children [1].